Pharma & Biotech
AI-generated weekly research reports from primary sources. · 8 reports
Pharma & Biotech
The final weeks of June 2026 brought a record-pace pharma M&A surge ($134 billion in H1 2026), a wave of new regulatory milestones including EMA CHMP recommendations and FDA approvals, and intensifyin…
Pharma & Biotech
The G7 Summit concluded with a landmark first-ever cancer declaration and industry mobilization around the Ebola Bundibugyo outbreak intensified, with named companies advancing therapeutics and vaccin…
Pharma & Biotech
The mid-June 2026 pharma and biotech landscape is marked by J&J's expansion of its nipocalimab autoimmune franchise with pivotal wAIHA data and acquisition of Firefly Bio for oncology pipeline strengt…
Pharma & Biotech
The early June 2026 pharma and biotech landscape is defined by new autoimmune and metabolic pipeline breakthroughs — including J&J's nipocalimab Phase 2 SLE data and Pfizer's monthly-dosed GLP-1 berob…
Pharma & Biotech
ASCO 2026 dominated the late May 2026 pharma reporting period, with J&J, Pfizer, and Revolution Medicines delivering practice-changing oncology data across multiple tumor types, while Japan's declinin…
Pharma & Biotech
The May 2026 pharma and biotech landscape is defined by EMA's recommendation of eight new medicines, widening EU medicine access inequality per EFPIA's WAIT report, and coordinated global policy actio…
Pharma & Biotech
The pharma and biotech landscape in mid-May 2026 is marked by deepening FDA leadership upheaval — with both the Commissioner and CDER chief now departed — alongside the finalization of the EU Critical…
Pharma & Biotech
This baseline report covers the pharma and biotech sector in mid-2026, highlighting AI-driven drug discovery advances, major regulatory shifts including FDA leadership instability, landmark EU legisla…